Direct Flow Medical, maker of a minimally-invasive device to treat heart valve disease, has raised $40 million of a targeted $42.5 million third round of venture funding, according to a filing with the SEC. Based in Santa Rosa, Calif., the company is backed by Johnson & Johnson Development Corp., Foundation Medical Partners, VantagePoint Venture Partners, ePlanet Ventures, EDF Ventures, New Leaf Venture Partners and Spray Venture Partners. It has raised $75 million to date.